MARKET

MNPR

MNPR

Monopar Therapeutics Inc
NASDAQ
87.68
+0.05
+0.06%
Closed 18:49 06/26 EDT
OPEN
87.64
PREV CLOSE
87.63
HIGH
92.26
LOW
85.70
VOLUME
310.27K
TURNOVER
0
52 WEEK HIGH
105.00
52 WEEK LOW
29.18
MARKET CAP
587.37M
P/E (TTM)
-46.1814
1D
5D
1M
3M
1Y
5Y
1D
Monopar Highlights Positive Phase 3 Wilson Disease Data
TipRanks · 2d ago
Monopar Therapeutics announces new FoCus trial analyses
TipRanks · 2d ago
Monopar Therapeutics To Present New Analyses From Phase 3 FoCus Randomized Clinical Trial Of ALXN1840 At EAN 2026.
Benzinga · 2d ago
Monopar says Phase 3 FoCus analysis shows ALXN1840 outperforms standard care in neurologic Wilson disease patients
PUBT · 2d ago
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
Barchart · 2d ago
Top Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment
NASDAQ · 5d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 5d ago
Monopar Shareholders Approve Directors, Pay and Incentive Plan
TipRanks · 5d ago
More
About MNPR
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Webull offers Monopar Therapeutics Inc stock information, including NASDAQ: MNPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MNPR stock methods without spending real money on the virtual paper trading platform.